Recombinant Murine TRAIL
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | TRAIL is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic “death domain”, which activates the cell’s apoptotic machinery. Recombinant murine TRAIL is a 174 amino acid polypeptide (20.0 kDa), consisting of the TNF homologous portion of the extracellular domain of the full length TRAIL protein. |
---|---|
BiologicalActivity | Assay#1:Determined by the dose-dependent stimulation of MIP-2 production by M spleen cells using a concentration range of 10-100 ng/ml. Assay#2:Measured by its ability to induce apoptosis in LN-18 cells (human glioblastoma cells). The expected ED50 for this effect is 40.0-60.0 ng/ml. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Murine TRAIL is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.